Skip to content

CopiOs Posterolateral Fusion Procedure

A Prospective Study Assessing Clinical Outcomes and Radiographic Results After the Use of CopiOs(R) Bone Void Filler (BVF)Sponge in a Posterolateral Fusion Procedure (PLF).

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01123850
Enrollment
45
Registered
2010-05-14
Start date
2010-06-30
Completion date
2012-10-31
Last updated
2015-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spondylolisthesis, Stenosis

Keywords

CopiOs, Degenerative spondylolisthesis,, stenosis with instability, or, degenerative disc disease as diagnosed by radicular signs and/or imaging studies

Brief summary

To compare radiographic data collection from patients undergoing instrumented PLF with CopiOs(R) BVF or instrumented PLF with autologous bone and to assess overall clinical outcomes. Patients will serve as self controls.

Detailed description

This is a prospective, counter-balanced study involving 85 subjects at up to 8 investigative centers. Each subject will be an appropriate candidate for an instrumented PLF and will meet the inclusion and exclusion criteria. All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study. Data will be collected pre-operatively, operatively and post-operatively at six and twelve months. The study objectives include: Radiographic success of CopiOs is non-inferior to autograft with clear evidence of bridging bone. Radiographic analysis will be used to show that CopiOs works as well as autograft when comparing the rate of fusion at 6 and 12 months. The CT scan (12 month) will show that CopiOs works as well as autograft when comparing the fusion mass between the transverse processes. Additionally, clinical success will be determined by an improvement of 15 percentage points using the Oswestry Disability Index and maintenance or improvement in the motor and sensory components of the neurological assessment from preoperative to postoperative. Since patients serve as self-controls there will be no clinical success comparisons between the groups. Rather, clinical success will be measured on overall improvement based on patient outcomes.

Interventions

DEVICECopios

Bone Void Filler

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patient must be skeletally mature; between the ages of 21 and 75 * Patients having degenerative spondylolisthesis, stenosis with instability, or degenerative disc disease as diagnosed by radicular signs and/or imaging studies * Patients will be medically indicated for a single-level, instrumented PLF between L2 and S1 per their surgeon * Patient must be willing and able to comply with study requirements, including all necessary study related paperwork and follow-up visits

Exclusion criteria

* Use of iliac crest bone graft; * Any previous lumbar spinal surgeries at indicated level; * Any medical or physical condition that would preclude the potential benefit of spinal surgery; * Use of a dynamic stabilization systems; * Sites where stresses on void will exceed the load strength of fixation of hardware; * Segmental defects; * Significantly impaired vascularity proximal to the surgical site; * Sites in direct contact with articular space; * Soft tissue deficit not allowing closure; * Active systemic or local infection; * Severe degenerative bone disease; * Patients with osteoporosis who are actively under treatment; * Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI\>40 kg/m2); * Active malignancy; * Patients with a history of multiple allergies; * Patients with known allergies to bovine collagen; * Hypercalcemia; * Pregnancy; * Mental illness; * Alcohol or drug abuse; * Incarceration.

Design outcomes

Primary

MeasureTime frameDescription
Fusion Assessment6 M, 12 MFusion at 12M using radiograph Fusion Mass at 12M using CT

Secondary

MeasureTime frame
Outcome Measure - Pain, Life Quality, SatisfactionPreOp, Surgery, 6M, 12M

Countries

United States

Participant flow

Participants by arm

ArmCount
Single ARM - Copios Bone Filler
All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study. Copios: Bone Void Filler
45
Total45

Withdrawals & dropouts

PeriodReasonFG000
Overall StudySlow enrollment45

Baseline characteristics

CharacteristicSingle ARM - Copios Bone Filler
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
45 Participants
Region of Enrollment
United States
45 participants
Sex: Female, Male
Female
NA Participants
Sex: Female, Male
Male
NA Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 45
serious
Total, serious adverse events
0 / 45

Outcome results

Primary

Fusion Assessment

Fusion at 12M using radiograph Fusion Mass at 12M using CT

Time frame: 6 M, 12 M

Population: Study was terminated due to slow enrollment, there was no data analysis

Secondary

Outcome Measure - Pain, Life Quality, Satisfaction

Time frame: PreOp, Surgery, 6M, 12M

Population: Study was terminated due to slow enrollment, there was no data analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026